Cytotoxicity of lymphokine-activated and freshly obtained T cells and their sensitivity to specified antibodies
| Group . | Cytotoxicity . | ||||
|---|---|---|---|---|---|
| Basal . | + anti-Tag . | + anti-Hsp . | + anti-FasL . | + anti-Fas . | |
| LAK cells | |||||
| Total | 38 ± 3 | 17 ± 3 | 18 ± 2 | 4 ± 0.4 | 2.5 ± 0.3 |
| Total* | 42 ± 0.4 | 20 ± 2 | 19 ± 2 | 3 ± 0.9 | 3 ± 0.9 |
| CD4−CD8− | 4 ± 0.4 | ND | ND | ND | ND |
| CD4− | 24 ± 2 | 23 ± 3 | 25 ± 3 | 3 ± 0.4 | ND |
| CD8− | 21 ± 2 | 3 ± 0.3 | 4 ± 0.6 | 4 ± 0.4 | ND |
| CD4+ (ps) | 18 ± 2 | 4 ± 0.4 | 3 ± 0.3 | 5 ± 0.7 | ND |
| CD4+ (ps)* | 20 ± 2 | 3 ± 0.4 | 3 ± 0.2 | 4 ± 0.4 | ND |
| CD4+ (ns) | 16 ± 2 | 3 ± 0.3 | 3 ± 0.3 | 4 ± 0.6 | 3.5 ± 0.7 |
| CD8+ (ps) | 17 ± 2 | 15 ± 1 | 16 ± 1 | 3.5 ± 0.5 | ND |
| CD8+ (ns) | 19 ± 2 | 17 ± 2 | 19 ± 2 | 4 ± 0.6 | ND |
| CD4+CD25− | 3 ± 0.3 | ND | ND | ND | ND |
| CD4+CD25+ | 17 ± 2 | 3 ± 0.4 | 4 ± 0.9 | 4 ± 0.7 | 4 ± 0.4 |
| CD4+CD25+* | 19 ± 3 | 2 ± 0.3 | 4 ± 0.8 | 3 ± 0.7 | ND |
| CD4+CD25+Tag− | 4 ± 0.5 | ND | ND | ND | ND |
| Donor PBMCs | |||||
| Total | 25 ± 2 | 4 ± 0.4 | 3 ± 0.9 | 5 ± 0.6 | 3 ± 0.6 |
| Total* | 27 ± 2 | 5 ± 0.5 | 3 ± 0.9 | 4 ± 0.6 | ND |
| CD8− | 24 ± 2 | 3 ± 0.3 | 5 ± 0.5 | 4 ± 0.6 | ND |
| CD8+ | 5 ± 0.9 | ND | ND | ND | ND |
| CD4− | 6 ± 0.7 | ND | ND | ND | ND |
| CD4+ | 27 ± 2 | 4 ± 0.4 | 4.5 ± 0.5 | 3 ± 0.3 | ND |
| CD4+CD25− | 9 ± 1 | 2 ± 0.1 | 1.5 ± 0.1 | 3 ± 0.3 | ND |
| CD4+CD25+ | 26 ± 2 | 3 ± 0.6 | 5 ± 0.5 | 4 ± 0.4 | ND |
| CD4+CD25+* | 27 ± 3 | 4 ± 0.4 | 3 ± 0.7 | 4 ± 0.9 | 3 ± 0.9 |
| Group . | Cytotoxicity . | ||||
|---|---|---|---|---|---|
| Basal . | + anti-Tag . | + anti-Hsp . | + anti-FasL . | + anti-Fas . | |
| LAK cells | |||||
| Total | 38 ± 3 | 17 ± 3 | 18 ± 2 | 4 ± 0.4 | 2.5 ± 0.3 |
| Total* | 42 ± 0.4 | 20 ± 2 | 19 ± 2 | 3 ± 0.9 | 3 ± 0.9 |
| CD4−CD8− | 4 ± 0.4 | ND | ND | ND | ND |
| CD4− | 24 ± 2 | 23 ± 3 | 25 ± 3 | 3 ± 0.4 | ND |
| CD8− | 21 ± 2 | 3 ± 0.3 | 4 ± 0.6 | 4 ± 0.4 | ND |
| CD4+ (ps) | 18 ± 2 | 4 ± 0.4 | 3 ± 0.3 | 5 ± 0.7 | ND |
| CD4+ (ps)* | 20 ± 2 | 3 ± 0.4 | 3 ± 0.2 | 4 ± 0.4 | ND |
| CD4+ (ns) | 16 ± 2 | 3 ± 0.3 | 3 ± 0.3 | 4 ± 0.6 | 3.5 ± 0.7 |
| CD8+ (ps) | 17 ± 2 | 15 ± 1 | 16 ± 1 | 3.5 ± 0.5 | ND |
| CD8+ (ns) | 19 ± 2 | 17 ± 2 | 19 ± 2 | 4 ± 0.6 | ND |
| CD4+CD25− | 3 ± 0.3 | ND | ND | ND | ND |
| CD4+CD25+ | 17 ± 2 | 3 ± 0.4 | 4 ± 0.9 | 4 ± 0.7 | 4 ± 0.4 |
| CD4+CD25+* | 19 ± 3 | 2 ± 0.3 | 4 ± 0.8 | 3 ± 0.7 | ND |
| CD4+CD25+Tag− | 4 ± 0.5 | ND | ND | ND | ND |
| Donor PBMCs | |||||
| Total | 25 ± 2 | 4 ± 0.4 | 3 ± 0.9 | 5 ± 0.6 | 3 ± 0.6 |
| Total* | 27 ± 2 | 5 ± 0.5 | 3 ± 0.9 | 4 ± 0.6 | ND |
| CD8− | 24 ± 2 | 3 ± 0.3 | 5 ± 0.5 | 4 ± 0.6 | ND |
| CD8+ | 5 ± 0.9 | ND | ND | ND | ND |
| CD4− | 6 ± 0.7 | ND | ND | ND | ND |
| CD4+ | 27 ± 2 | 4 ± 0.4 | 4.5 ± 0.5 | 3 ± 0.3 | ND |
| CD4+CD25− | 9 ± 1 | 2 ± 0.1 | 1.5 ± 0.1 | 3 ± 0.3 | ND |
| CD4+CD25+ | 26 ± 2 | 3 ± 0.6 | 5 ± 0.5 | 4 ± 0.4 | ND |
| CD4+CD25+* | 27 ± 3 | 4 ± 0.4 | 3 ± 0.7 | 4 ± 0.9 | 3 ± 0.9 |
Data are mean percentages plus and minus the SEM (n = 3-5). Cytotoxicity is given as the percentage of K562 cells killed within 3 hours of standard incubation.
ps indicates positive mode of cell selection with antibody-coated magnetic beads; ns, negative mode of cell selection with antibody-coated magnetic beads; and ND, not determined.
MOLT-4 as target cells.